Premium
Radiolabelling of pharmaceutical dosage forms by neutron activation of samarium‐152
Author(s) -
Awang M B,
Hardy J G,
Davis S S,
Wilding I R,
Parry S J
Publication year - 1993
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.2580331008
Subject(s) - samarium , chemistry , radiochemistry , neutron activation , nuclear chemistry , oxide , yield (engineering) , neutron , neutron flux , inorganic chemistry , organic chemistry , metallurgy , nuclear physics , materials science , physics
Samarium‐152 can be activated in a neutron flux for the labelling of pharmaceutical dosage forms for evaluation by gamma scintigraphy. The samarium is incorporated as samarium oxide powder which is available with 152 Sm in its natural isotopic abundance or isotopically enriched. The yield of 153 Sm was reduced considerably following the neutron activation of the non‐isotopically enriched oxide. This can be attributed to the high neutron capture by 149 Sm present in the non‐isotopically enriched oxide. In order to keep the mass of the added oxide powder to the minimum and also to reduce the neutron irradiation time, it is recommended that samarium oxide enriched with 152 Sm should be used routinely when radiolabelling pharmaceutical dosage forms.